ArQule Reports First Quarter 2016 Financial Results
04 mai 2016 07h00 HE
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...
ArQule Reports Fourth Quarter and Full Year 2015 Financial Results
29 févr. 2016 07h00 HE
|
ArQule, Inc.
Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...
ArQule to Present at Upcoming Investor Conferences
04 févr. 2016 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
28 janv. 2016 07h30 HE
|
ArQule, Inc.
First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndromeArQule receives Investigational New Drug approval for ARQ 751BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc....
ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
17 nov. 2015 07h30 HE
|
ArQule, Inc.
ArQule receives orphan drug designation for ARQ 092 in Proteus syndrome BURLINGTON, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) and the National Human Genome Research...
ArQule Reports Third Quarter 2015 Financial Results
04 nov. 2015 07h00 HE
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., Nov. 04, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of...
ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference
28 sept. 2015 07h30 HE
|
ArQule, Inc.
Preliminary Results of the Phase 1b Expansion Cohort Show Four Partial Responses in Targeted Patient Populations BURLINGTON, Mass., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc....